- Home
- GLO vs IPHA Comparison
GLO vs IPHA Comparison
Compare GLO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLO
- IPHA
- Stock Information
- Founded
- GLO 2006
- IPHA 1999
- Country
- GLO United States
- IPHA France
- Employees
- GLO N/A
- IPHA N/A
- Industry
- GLO Finance/Investors Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- GLO Finance
- IPHA Health Care
- Exchange
- GLO Nasdaq
- IPHA Nasdaq
- Market Cap
- GLO 193.7M
- IPHA 160.1M
- IPO Year
- GLO N/A
- IPHA 2019
- Fundamental
- Price
- GLO $5.03
- IPHA $2.43
- Analyst Decision
- GLO
- IPHA Strong Buy
- Analyst Count
- GLO 0
- IPHA 1
- Target Price
- GLO N/A
- IPHA $11.00
- AVG Volume (30 Days)
- GLO 170.5K
- IPHA 31.8K
- Earning Date
- GLO 01-01-0001
- IPHA 03-27-2025
- Dividend Yield
- GLO 11.38%
- IPHA N/A
- EPS Growth
- GLO N/A
- IPHA N/A
- EPS
- GLO N/A
- IPHA N/A
- Revenue
- GLO N/A
- IPHA $20,831,349.00
- Revenue This Year
- GLO N/A
- IPHA $209.83
- Revenue Next Year
- GLO N/A
- IPHA $83.96
- P/E Ratio
- GLO N/A
- IPHA N/A
- Revenue Growth
- GLO N/A
- IPHA N/A
- 52 Week Low
- GLO $4.08
- IPHA $1.29
- 52 Week High
- GLO $5.18
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- GLO 60.48
- IPHA 67.63
- Support Level
- GLO $4.98
- IPHA $2.22
- Resistance Level
- GLO $5.06
- IPHA $2.45
- Average True Range (ATR)
- GLO 0.07
- IPHA 0.14
- MACD
- GLO 0.03
- IPHA 0.03
- Stochastic Oscillator
- GLO 90.62
- IPHA 82.52
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.